As we recently published that a cytotoxic CD56bright anti-tumor NK cell subpopulation was activated in the presence of BCG [6], and the CXCL10 blockade has been described to decrease the cytotoxic recognition of NK cells [14], we studied the effect of increasing the concentrations of CXCL10 on the activation of NK cells present in the peripheral blood mononuclear cells from healthy donors (Supplementary Figure S3). Here, CXCL10 is linked to neoplasm.